BioCentury | Jun 26, 2020
Distillery Therapeutics

Increasing PXR activity to treat acute kidney injury

DISEASE CATEGORY: Renal INDICATION: Renal damage Promoting the activity of the transcription factor PXR could treat acute kidney injury (AKI). PXR protein levels in renal tubular cells were lower in kidney biopsies from 20 AKI...
BioCentury | Aug 29, 2019
Translation in Brief

Cytomegalovirus vectors for a prophylactic HIV vaccine

A spread-deficient cytomegalovirus carrying SIV antigens evoked long-term protective immunity against successive SIV infections in monkeys, suggesting that a prophylactic HIV vaccine can be developed in humans using a similar strategy. While academics and companies...
BioCentury | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
BioCentury | Feb 6, 2019
Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Fruit fly studies suggest promoting BMPRI or BMP7 expression could help treat ALS. In a Drosophila model of ALS expressing mutant SOD1, overexpression of the Drosophila ortholog of human BMPRI...
BioCentury | Jan 18, 2019
Product R&D

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address. On Jan. 3, Vertex announced a deal...
BioCentury | Aug 14, 2018
Translation in Brief

Primate predictions

A team at Illumina Inc. (NASDAQ:ILMN) has developed an AI algorithm that will help identify pathogenic mutations from genome sequencing analyses by including non-human primate data in the training data set, and the approach could...
BioCentury | May 11, 2018
Financial News

Column Group leads Escient's $40M series A

Escient Pharmaceuticals Inc. (San Diego, Calif.) raised $40 million in a series A round led by The Column Group. Also participating were 5AM Ventures and Osage University Partners. Escient is developing compounds targeting GPCRs, including...
BioCentury | May 9, 2018
Financial News

Column Group leads Escient's $40M series A

Escient Pharmaceuticals Inc. (San Diego, Calif.) raised $40 million in a series A round led by The Column Group. Also participating were 5AM Ventures and Osage University Partners. Escient is developing compounds targeting GPCRs, including...
BioCentury | Mar 29, 2018
Tools & Techniques

Cutting-edge diagnostics

Following the splash that CRISPR has made in the world of therapeutics, academics are expanding the tool kit of Cas enzymes and finding new uses in diagnostics. Early hints suggest the technology could become competitive,...
BioCentury | Mar 16, 2018
Preclinical News

New Cas enzyme can edit RNA, target tau

In Cell , researchers from the Salk Institute for Biological Studies discovered a new RNA-targeting CRISPR enzyme, CRISPR-associated protein 13d (Cas13d), and showed it could be used to edit the transcript of a frontotemporal dementia target,...
Items per page:
1 - 10 of 141
BioCentury | Jun 26, 2020
Distillery Therapeutics

Increasing PXR activity to treat acute kidney injury

DISEASE CATEGORY: Renal INDICATION: Renal damage Promoting the activity of the transcription factor PXR could treat acute kidney injury (AKI). PXR protein levels in renal tubular cells were lower in kidney biopsies from 20 AKI...
BioCentury | Aug 29, 2019
Translation in Brief

Cytomegalovirus vectors for a prophylactic HIV vaccine

A spread-deficient cytomegalovirus carrying SIV antigens evoked long-term protective immunity against successive SIV infections in monkeys, suggesting that a prophylactic HIV vaccine can be developed in humans using a similar strategy. While academics and companies...
BioCentury | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
BioCentury | Feb 6, 2019
Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Fruit fly studies suggest promoting BMPRI or BMP7 expression could help treat ALS. In a Drosophila model of ALS expressing mutant SOD1, overexpression of the Drosophila ortholog of human BMPRI...
BioCentury | Jan 18, 2019
Product R&D

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address. On Jan. 3, Vertex announced a deal...
BioCentury | Aug 14, 2018
Translation in Brief

Primate predictions

A team at Illumina Inc. (NASDAQ:ILMN) has developed an AI algorithm that will help identify pathogenic mutations from genome sequencing analyses by including non-human primate data in the training data set, and the approach could...
BioCentury | May 11, 2018
Financial News

Column Group leads Escient's $40M series A

Escient Pharmaceuticals Inc. (San Diego, Calif.) raised $40 million in a series A round led by The Column Group. Also participating were 5AM Ventures and Osage University Partners. Escient is developing compounds targeting GPCRs, including...
BioCentury | May 9, 2018
Financial News

Column Group leads Escient's $40M series A

Escient Pharmaceuticals Inc. (San Diego, Calif.) raised $40 million in a series A round led by The Column Group. Also participating were 5AM Ventures and Osage University Partners. Escient is developing compounds targeting GPCRs, including...
BioCentury | Mar 29, 2018
Tools & Techniques

Cutting-edge diagnostics

Following the splash that CRISPR has made in the world of therapeutics, academics are expanding the tool kit of Cas enzymes and finding new uses in diagnostics. Early hints suggest the technology could become competitive,...
BioCentury | Mar 16, 2018
Preclinical News

New Cas enzyme can edit RNA, target tau

In Cell , researchers from the Salk Institute for Biological Studies discovered a new RNA-targeting CRISPR enzyme, CRISPR-associated protein 13d (Cas13d), and showed it could be used to edit the transcript of a frontotemporal dementia target,...
Items per page:
1 - 10 of 141